Technology - AbVision

Contents

1 Our Technology

Our Technology

AbVision has successfully developed proprietary drug technology platforms for generating next generation of bio-therapeutics. Using our emerging platforms, AVI is able to advance numerous innovative drug candidates in cancer therapy and infectious diseases.

Therapeutic Antibody

SpeedyAb™ technology platform provides high-throughput features of antibody screening for obtaining the therapeutic leads with high affinity and broad diversity.

Competitive Strength

	Current Hurdles	SpeedyAb™
Immunogen	Be subject to cross-react with other homologies Require large amount immunogens (> 0.5 mg)	Highly specific Trace amount sufficient (< 0.1 mg)
Immunization	Require repeated injection schedules Long lead time (2-3 months) Co-injection of adjuvants required Low to moderate immunogenicity Low to moderate degree of affinity maturation	Significantly reduce times of injections Short lead time (1-1.5 months) Platform-derived high immunogenicity High degree of affinity maturation
Screening	Low throughput and labor intensive Functional screening infeasible	Feasible for high throughput Speedily identify the clones with biological activities

Vaccine

ImmunoBuster I+II™ technology platform develops powerful vaccines with strong immunogenicity for prophylactic and therapeutic treatment without repeated immunization required. An Immunological module for eliciting quick yet robust immunity and is comparable with commercially available vaccine.

Competitive Strength

	Current Hurdles	ImmunoBuster I+II™
Vaccination	Multiple immunization schedules required Mainly for prophylactic use Less effects of dose regimens and doses	Single or double immunization sufficient Feasibility for prophylaxis and therapeutics Low amount sufficient for an effective dose Improvement of PK profile
Response	Slow immune response against targets of our choice Less persistence and functionality of innate and antigen-specific immune response	Quick immune response against targets of our choice Good persistence/long lasting of immune response Strong non-Ag-driven innate and antigen-specific immune responses

Cell Therapy

TsKill™ technology platform empowers rare tumor-reactive T cells to effectively destroy tumors by enhancing the functionality of effector cells and tumor recognition.

	Current Hurdles	TsKill™
Administration	Autologous cell infusion required	Availability for ex vivo expansion for cell infusion Feasibility for in vivo expansion tumor-specific T cells
Response	Low number of tumor-specific T cells Less potent of effector functions Possible oncogenic off-target effects	Significantly increase the quantity tumor-specific T cells Significantly enhance the quality/effector functions of tumor-specific T cells Less concern of off-target effects
Production	Genetic engineering of immune cells required Virus transduction or electroporation required Big burden on CMC process (QA/QC) Time-consuming and costly Infeasibility of quickly switching targets	No transduction and transfection required One-step expansion tumor-specific T cells Less complex on CMC process (QA/QC) Reduce time and cost significantly Quickly apply on various tumor-associated/specific Ags